CJC-1295 + IPA
CJC-1295/Ipamorelin is a dual-compound research blend combining a modified 29-amino acid GHRH analog with a selective 5-amino acid ghrelin mimetic. Together these compounds engage GHRH receptors and GHSR-1a receptors respectively, allowing researchers to examine synergistic GH axis signaling in controlled laboratory models. Supplied as a lyophilized powder in a 3mL vial, it is intended exclusively for in vitro laboratory research by qualified scientific personnel.
This combination has been utilized in preclinical studies examining GHRH receptor binding kinetics, GHSR-1a receptor selectivity, pituitary somatotroph cell function, and complementary growth hormone axis signaling pathways — independent of the broader endocrine effects associated with endogenous GHRH and ghrelin activity.
Product Details
- Form: Lyophilized powder (for laboratory research)
- Amount: 6 mg CJC-1295 + 6 mg Ipamorelin per vial
- Purity: ≥ 98% (HPLC tested)
- CJC-1295 Sequence: Modified GHRH (tetrasubstituted, 30 amino acids)
- Molecular Formula: C₁₅₂H₂₅₂N₄₄O₄₂
- Molecular Weight: ~3367 Da
- Ipamorelin Sequence: Aib-His-D-2-Nal-D-Phe-Lys-NH₂ (5 amino acids)
- Molecular Formula: C₃₈H₄₉N₉O₅
- Molecular Weight: ~711.9 Da
- Intended Use: Laboratory research only
DISCLAIMER: This product is strictly to be used for scientific research use only. It is not for human consumption and the FDA has not approved the use for diagnostic, therapeutic, or medical purposes.
We recommend you review our Terms of Service if you have questions about product use.
